Trial Library has raised $10 million in Series A funding co-led by SemperVirens Venture Capital and Next Ventures, with participation from Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest, Overwater Ventures, and others. The round brings total funding to $15 million.
Trial Library is an AI-powered platform that connects patients with clinical trials through community-based clinical settings. The company currently operates across 320+ clinics and 1,500+ providers nationwide.
“As a physician-scientist, I witnessed, first-hand, the significant impact clinical trials have on improved healthcare outcomes,” said Dr. Hala Borno, CEO and founder of Trial Library. “At Trial Library, we’re building the connective tissue that links care delivery and clinical research. This latest funding will enable us to advance our model where access to innovation is the standard, not the exception.”
The platform uses AI-enabled provider activation, compliant eligible patient identification, and longitudinal navigation throughout the trial lifecycle. Trial Library is expanding partnerships with payers including self-insured plans and health plans.
“Trial Library is the first technology company to unlock the payer market to effectively broaden the pool of patients who are considered for clinical trials,” said Allison Baum Gates, general partner of SemperVirens Venture Capital. “We’re excited to back a platform that aligns incentives and unites patients, providers, payers, and life-science partners around shared cost-savings and patient outcomes.”
Since launching in 2022, Trial Library has demonstrated impact through strategic partnerships. The company’s work with The Oncology Institute generated 642 patient referrals in one year. Partnerships with American Oncology Network have identified tens of eligible patients for solid tumor trials in the first quarter of implementation.
“Trial Library is a uniquely end-to-end platform, building the AI infrastructure that is accelerating access to the next generation of precision medicine,” said Cris De Luca, partner at Sanofi Ventures.
Trial Library has expanded its collaboration with Johnson & Johnson Innovative Medicine to support oncology clinical development and medical affairs programs. In 2025, the company announced a collaboration with Texas Oncology to streamline clinical trial access through personalized patient navigation.
The platform focuses on diversity and equity among patient populations, including underserved populations. Trial Library reports that 69% of patient referrals are non-white, 29% are on Medicaid, and 44% require transportation support. This addresses gaps in clinical trial participation while reducing administrative burden on providers.
“Trial Library’s approach aligns with the growing shift toward decentralized, community-based research,” said Lance Armstrong, managing partner at Next Ventures. “They’re proving that AI and human navigation together can bring precision medicine to every corner of healthcare.”
